The Ferumoxytol for Anemia of CKD Trial (FACT)—a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale
Abstract Background Iron deficiency anemia (IDA) is a common manifestation of chronic kidney disease (CKD), affecting most patients on hemodialysis and imposing a substantial clinical burden. Treatment with iron supplementation increases hemoglobin levels and can reduce the severity of anemia in pat...
Main Authors: | Iain C. Macdougall, Naomi V. Dahl, Kristine Bernard, Zhu Li, Alka Batycky, William E. Strauss |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-04-01
|
Series: | BMC Nephrology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12882-017-0523-8 |
Similar Items
-
Correction to: The Ferumoxytol for Anemia of CKD Trial (FACT)—a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale
by: Iain C. Macdougall, et al.
Published: (2018-04-01) -
Efficacy and safety of IV ferumoxytol for iron deficiency anemia in patients with cancer
by: Vadhan-Raj S, et al.
Published: (2017-12-01) -
Comparative safety of intravenous Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions
by: Adkinson NF, et al.
Published: (2017-09-01) -
The Emerging Role of Ferumoxytol-Enhanced MRI in the Management of Cerebrovascular Lesions
by: David Hasan, et al.
Published: (2013-08-01) -
Ferumoxytol-enhanced cardiovascular magnetic resonance detection of early stage acute myocarditis
by: Yuko Tada, et al.
Published: (2019-12-01)